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Introduction
Formation of new blood vessels (angiogenesis) and con-
trol of blood vessels sprouting  (anti-angiogenesis) are
fundamental to human health, as they play key roles in
many physiological and pathological conditions. 
Angiogenesis is a basic process in embryo devel-
opment - responsible for organogenesis as well as in
function and development of placenta, endometrium
and corpus luteum [1,2]. 
It also plays a crucial role in wound healing as well
as in diabetic retinopathy [3], rheumatoid arthritis [4]
and tumor growth and metastasis formation [5]. 
The initial signals for blood vessel sprouting
towards embryo tissues are unknown, but tissue
hypoxia is believed to be critical for commencement of
the angiogenic cascade.
The development of the embryo occurs in close
association with and proximity to capillary ingrowth.
In recent years an increase has been observed in the
interest in drugs of natural origin having immunotrop-
ic activity. They may be a valuable complementation
to treatment of infection, increasing cellular and
humoral immunity of the organism in various clinical
situations. Echinacea purpurea-based phytoceuticals
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Abstract: The process of angiogenesis and control of blood vessels sprouting  are fundamental to human health, as they
play key roles in many physiological and pathological conditions. Intake of different pharmaceuticals with antiangio-
genic activity by pregnant women may lead to severe developmental disturbances as it was described in case of thalido-
mide.  It may also cause immunomodulatory effects as it was shown for antibiotics, theobromine, caffeic acid or cate-
chins on the pregnant mice model. At present, Echinacea purpurea-based phytoceuticals are among the most popular
herbals in the marketplace. Many compounds of Echinacea extracts (polysaccharides, alkamides, polyphenols, glyco-
proteins) exert immunomodulatory, anti-oxidative and anti-inflammatory activity. Echinacea is one of the most power-
ful and effective remedies against many kinds of bacterial and viral infections. In previous studies we had shown sig-
nificant inhibitory effect of the Echinacea purpurea based remedy on tumour angiogenic activity using cutaneous
angiogenesis test, and an inhibitory effect on L-1 sarcoma growth was observed .The aim of the present study was to
establish whether pharmaceuticals containing alcoholic extracts of Echinacea purpurea given to pregnant mice influ-
ence angiogenic activity and tissue VEGF and bFGF production of their fetuses. We showed that angiogenic activity of
tissue homogenates was increased in Esberitox group and diminished in case of Immunal forte as compared to standard
diet group. In case of Echinapur group we did not find significant differences in angiogenic activity. VEGF and bFGF
concentration were lower in all groups compared to the control. In the case of Echinapur and Esberitox number of fetus-
es in one litter were slightly lower as compared to control group, but the difference is on the border of statistical sig-
nificance. In conclusion, there is some possibility that pharmaceuticals containing Echinacea purpurea might influence
fetal development in human also, because they may interfere with embrional angiogenesis , and should not be recom-
mended for pregnant women. 
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are among the most popular herbals in the marketplace.
Many compounds of Echinacea extracts (polysaccha-
rides, alkamides, polyphenols, glycoproteins) exert
immunomodulatory, anti-oxidative and anti-inflamma-
tory activity [6,7]. Echinacea is one of the most pow-
erful and effective remedies against many kinds of
bacterial and viral infections. Several investigators
describe stimulation by Echinacea extracts of various
parameters of cellular and humoral immunity in differ-
ent experimental models [8-14]. Different species of
Echinacea, the part of the plant processed and the pro-
cessing procedure are variables influencing its effec-
tiveness and mode of action. However, many experts
consider the juice and hydro-alcoholic extracts of
Echinacea purpurea, in liquid or desiccated form
(tablets), the best preparation, having the greatest level
of clinical value [15]. 
Echinacea sp. products are shown as safe and
harmless pharmaceuticals even during pregnancy.
However, there is insufficient knowledge concerning
the effects of using Echinacea species herbals in above
period. While some data indicates that fetal malforma-
tions do not occur during pregnancy in humans con-
suming this herb [16], there are no formal studies
aimed at assessing the possibility that Echinacea
herbals intake may promote congenital abnormalities
or fetal growth retardation.
In the previous studies we have shown significant
inhibitory effect of the Echinacea purpurea based
remedy on tumour angiogenic activity using cutaneous
angiogenesis test, and an inhibitory effect on L-1 sar-
coma growth was observed [17].
The aim of the present study was to establish whether
pharmaceuticals containing desiccated alcoholic extracts
of Echinacea purpurea succus, given to pregnant mice,
influence number, angiogenic activity and tissue VEGF
and bFGF production of their18-day fetuses.
Materials and methods
Drugs. Immunal Forte tablets (LEK, Slovenia) batch 4676311F,
Echinapur tablets (Herbapol Poznañ) batch 010905 and Esberitox
tablets (GmbH,Germany) batch 623401.
Experimental protocol. Male and female 10-12-weeks old
inbred Balb/c mice, about 25 g of body mass, derived from the
breeding colony of Polish Academy of Sciences were matched
among themselves. Female mice from the 1st day of fertilization
until the 18th day of pregnancy were daily fed 0.6 mg of Echi-
nacea purpurea extract  dissolved in water (3 mothers were fed
Esberitox, 2 mothers were fed Immunal, 3 mothers were fed
Echinapur) or water as the control (four mothers), orally  by
Eppendorff pipette. 
On the 18th day of pregnancy mice were narcotized and sacri-
ficed, embryos were extracted and weighted. Embryos from one
litter were pooled, suspended in phosphate buffered saline (PBS)
1g per 2 ml, homogenized (VirSonic ultrasound sonificator) and
frozen at -78°C for further evaluation.
Embryo-induced angiogenesis test (EIA). The test was per-
formed as previously described [18]. Briefly: 0.05 ml of
homogenate samples were injected intradermally to anaesthetized
(3.6% chloralhydrate, 0.1 ml per 10 g of body mass) syngeneic
Balb/c mice (material from one litter was injected to 2-3 mice).
Both flanks of each mouse were finely shaved with a razor blade,
each flank was injected 2-3 times. Homogenates  were supple-
mented with 0.05 ml/ml of 0.01% trypan blue in order to facilitate
recognition of injection sites. After 72 hours mice were sacrificed
and newly-formed blood vessels on the inner skin surface were
counted in the dissection microscope, at 6x magnification, in cen-
tral 1/3 of microscopic field. Identification of newly-formed ves-
sels  was based on the fact that they are thin, directed to the point
of injection, and differ from the background vasculature in their
tortuosity and divarications. 
Cytokines level estimation. Measurement of VEGF and bFGF
concentration in homogenates was done using ELISA test (R&D,
USA) according to producer's instructions. Homogenate of each
litter was tested in triplicate or quadriplicate for bFGF and  VEGF.
Optical density was measured at 450 nm.VEGF and bFGF con-
centrations were expressed as pg/ml.
Ethical issues. For all experiments animals were handled
according to the Polish law on the protection of animals and NIH
standards. Experiments were accepted by the local Ethical Com-
mittee. 
Statistics. Statistical evaluation of the data from experiments was
done by Statsoft, Inc. (1997) Statistika PL (Software system data
analysis), version 5. ANOVA was used to test whether there was
statistically significant difference in angiogenic activity, VEGF
and bFGF concentration  between groups of means (standard,
Esberitox, Echinapur and Immunal diet group). To confirm these
differences, the post hoc Tukey test for unbalanced designs was
used for multiple comparisons (p<0.05). 
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Table 1. The effect of Echinacea- based preparations given to pregnant mice  on the angiogenic activity and VEGF and bFGF concen-
tration in 18-days embryos tissues (n=number of fetuses)
Results
We showed that angiogenic activity of tissue
homogenates was highly significantly increased in
Esberitox group and diminished in case of Immunal
forte as compared to standard diet (Fig. 1 and Table 1).
VEGF and bFGF concentration were lower in all exam-
ined than in control groups (Figs. 2 and 3 and Table 1).
In the case of Echinapur and Esberitox  mean num-
ber of fetuses in one litter were slightly lower (7.6) as
compared to  Immunal-fed (9.5) and controls (10), but
the differences are on the border of statistical signifi-
cance  (0.05<p<0.1). 
Discussion
Echinacea sp. came from North America and were tra-
ditionally used by the Indians for a variety of diseases,
including mouth sores, colds, injuries, tooth pain and
insect-bites[15]. According to clinical studies and
spontaneous reporting programs adverse events with
Echinacea are not commonly reported. Most frequent-
ly gastrointestinal upsets and rashes were observed. In
rare cases, Echinacea can be connected with allergic
reactions. Currently it is believed that short-term use
of Echinacea is associated with a relatively good safe-
ty profile, with a slight risk of transient, reversible,
adverse events [19].
It was shown that Echinacea influence different
immunological features in animal models. Brousseau
and Miller [20] showed that regular intake of Echinacea
may be beneficial, because it maintains in an elevated
state NK cells, prime elements in immunosurveillance
against spontaneous-developing tumors, a phenomenon
which increases in frequency with progressive aging.
In our previous studies we showed that phytoceuti-
cals based on Echinacea sp. influence cell mediated
immunity as well as antibody production and granulo-
cytes activity [21].
Moreover there is a strong scientific evidence for
the use of Echinacea in respiratory tract infection
treatment. On the other hand there are no many publi-
cations concerning safety of Echinacea intake during
pregnancy and lactation [22]. 
The evaluation of phytoceuticals safety during
pregnancy and lactation seems to be of a great impor-
tance as according to some studies 36% women use
herbal products while pregnant [22].
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Fig. 1.  The effect of Echinacea feeding of pregnant mice on the
angiogenic activity of fetal tissue.
Fig. 2. The effect of Echinacea feeding of pregnant mice on the
VEGF content activity of fetal tissue.
Fig. 3. The effect of Echinacea feeding of pregnant mice on the
bFGF content of fetal tissue.
Maass and co-workers [23] investigated the inclu-
sion of the dried herb Echinacea purpurea as feed
additive in diets of sows, piglets, and grower/finisher
pigs on growth performance, blood picture, plasma
enzymes including proliferation of lymphocytes, anti-
body status, and protein and immune globulin content
of colostrum. They did not find significant differences
for growth performance, weight loss, blood picture,
plasma enzymes, and colostrum composition.  In our
experiment in mice we found that  two Echinacea
drugs (Esberitox and Echinapur) lowered number of
embryos in one litter but the results were on the border
of statistical significance. On the other hand Chow and
co-workers indicated in mice model that pregnancy-
induced elevation in splenic lymphocytes and nucleat-
ed erythroid cells was all but eliminated in those
females which consumed E. purpurea daily through-
out their pregnancy. Moreover, they found that con-
suming E. purpurea during pregnancy reduced the
number of viable fetuses [24]. 
Our recent studies suggest that the most important
mechanism influencing fetal development in case of
Echinacea sp. intake might be its influence on angio-
genic activity and pro-angiogenic cytokines content of
developing tissues. 
In our previous studies we showed that Echinapur
administration in mice (topically or subcutaneously)
caused increase of LIA (lymphocytes induced angio-
genesis). Moreover it caused increase of chemokinetic
activity of granulocytes and mononuclear cells [25].  
Additionally, we showed inhibitory effect of com-
plex remedy containing Echinacea purpurea on tumor
angiogenic activity and L-1 sarcoma growth [17].
The above results led to a suggestion that Echinacea
sp. may influence embrionic angiogenesis and in the
same time may cause developmental abnormalities. 
In the present study we showed statistically signif-
icant decrease of fetal tissue angiogenic activity in
Immunal Forte fed group. It may indicate possible
adverse effects of above phytoceutical on embryo
development. Echinapur did'nt influence this parame-
ter, and Esberitox enhanced angiogenic ability of
embryos tissues in EIA test, despite their lower than in
the control VEGF and bFGF content. It may suggests
the presence of  some angio-stimulatory compounds in
these drugs what is in agreement with our previous
studies on lymphocyte-induced angiogenesis [25].
Angiogenesis cascade is promoted by hypoxia of
tissues. As a result of hypoxia cells start to produce
cytokines and growth factors that cause proliferation
and migration of endothelial cells. VEGF (vascular
endothelial growth factor) and bFGF (basic fibroblast
growth factor) are known as the most potential angio-
genesis promoters. VEGF plays a crucial role in organo-
genesis (liver and pancreas induction, kidney glomeru-
lus, bone and nervous system development) [26]. 
Moreover VEGF and bFGF take part in placenta-
tion and cytotrophoblast proliferation during pregnan-
cy [27,28]. As we showed the influence of examined
phytoceuticals on angiogenic activity of embryo tis-
sues we decided also to evaluate their influence on
angiogenesis promoters (VEGF and bFGF). In all
examined cases (all phytoceuticals used) we showed
highly statistically significant decrease in VEGF and
bFGF concentration in fetal tisuues. It may lead to
decreased angiogenic activity and therefore to devel-
opmental abnormalities in offspring of Echinacea sp.
fed  mothers.
In conclusion it should be stressed that pharmaceu-
ticals containing Echinacea purpurea may influence
fetal  angiogenesis in murine experimental model and
without further studies should not be recommended for
pregnant women. 
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